Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold as Beyfortus) highly effective in reducing respiratory syncytial virus (RSV) related hospitalization in children under 5 years old.
CDC study shows nirsevimab effective in reducing RSV hospitalizations among young children
